6533b85cfe1ef96bd12bd1de
RESEARCH PRODUCT
Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib
Vittorina ZagonelVincenzo DadduzioDario D'agostinoMargherita RossiMario Domenico RizzatoMario Domenico RizzatoGiulia OrsiMario ScartozziAndrea Casadei‐gardiniAlessandro CucchettiPietro AndreonePietro AndreoneGiuseppe CabibboValeria GuarneriS. LonardiGiulia RovestiMargherita RiminiRanka VukoticCiro CelsaStefano CascinuPhilip J. Johnsonsubject
Sorafenibmedicine.medical_specialtybusiness.industryPharmaceutical ScienceHepatitis Cmedicine.diseaseGastroenterologyComplementary and alternative medicineInternal medicinemedicinePharmacology (medical)In patientNeutrophil to lymphocyte ratioAlpha-fetoproteinbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2020-05-20 | Liver Cancer International |